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Background: Iodine-123-β-CIT, a single-photon emission computed tomography (SPECT) ligand for dopamine
transporters (DATs), has been used for in vivo studies in humans, monkeys, and rats but has not yet been used
extensively in mice. To validate the imaging and analysis methods for preclinical DAT imaging, wild-type healthy
mice were scanned using 123I-β-CIT.
Methods: The pharmacokinetics and reliability of 123I-β-CIT in mice (n = 8) were studied with a multipinhole
SPECT/CT camera after intravenous injection of 123I-β-CIT (38 ± 3 MBq). Kinetic imaging of three mice was
continued for 7 h postinjection to obtain the time-activity curves in the striatum and cerebellum volumes. Five
mice had repeated measures 4 h post-123I-β-CIT injection to provide an indication of test-retest reliability. The same
five mice served as a basis for a healthy mean SPECT template.
Results: Specific binding of 123I-β-CIT within the mouse striatum could be clearly visualized with SPECT. The kinetics
of 123I-β-CIT was similar to that in previously published autoradiography studies. Binding potential mean values of
the test-retest studies were 6.6 ± 15.7% and 6.6 ± 4.6%, respectively, and the variability was 9%. The SPECT template
was aggregated from the first and second imaging of the test-retest animals. No significant difference between the
templates (P > 0.05) was found. From the test template, a striatal volume of 22.3 mm3 was defined.
Conclusions: This study demonstrates that high-resolution SPECT/CT is capable of accurate, repeatable, and
semiquantitative measurement of 123I-β-CIT DAT binding in the mouse brain. This methodology will enable further
studies on DAT density and neuroprotective properties of drugs in mice.
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Previously, sensitivity and resolution of the single-
photon emission computed tomography (SPECT) system
have been challenges in small-animal imaging. Currently,
the scanning time can be kept short enough to enable
dynamic acquisitions, due to the high level of detection
efficiency and excellent spatial resolution obtained by
multipinholes [1]. Here, we examined the feasibility of
dual-modality-dedicated small-animal SPECT/computed
tomography (CT) in submillimeter brain structures and
the advantage of dynamic acquisitions.* Correspondence: kim.bergstrom@helsinki.fi
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in any medium, provided the original work is pParkinson's disease (PD) is characterized by the pro-
gressive degeneration of nigrostriatal dopaminergic neu-
rons. This neurodegenerative process is associated with
a loss of striatal dopamine transporters (DATs) [2,3]. In
vivo measurement of DAT density with SPECT is an
early marker of dopaminergic cell loss in subjects with
PD [4-6]. 123I-2β-carbomethoxy-3β-(4-iodophenyl)tro-
pane (123I-β-CIT), a SPECT ligand for DATs, has not yet
been validated in mice, which are frequently induced to
model several diseases. Previous mouse studies are
ex vivo autoradiography works [7-9], in which follow-up
of the same animals was not possible and test-retest
measurement was disabled. Whereas, Mochizuki et al.
used a simple probe system offering only a single projec-
tion and therefore cannot differentiate between the brain
structures [10]. However, the full benefit of small-animals an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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of radiotracers that enable the following of physiological
processes over time in the same animal. In rats, such
quantification has been performed using clinical gamma
cameras [11,12]. The latest work was executed with a
modern small-animal multipinhole SPECT by taking
static images of the mouse brain [13]. In that work, the
used DAT tracer was 123I-2β-carbomethoxy-3β-(4-iodo-
phenyl)-N-(3-fluoropropyl)nortropane (FP-CIT; DatScan,
GE Healthcare Inc., Waukesha, WI, USA), which is di-
vergent from 123I-β-CIT, as will be discussed later in this
chapter. The aim of our study was to determine the
complimentary preclinical results since the kinetics be-
tween mice and rats may vary.
Absolute quantification of DATs in mice would require
full kinetic modeling, with invasive arterial blood sam-
pling and dynamic SPECT scanning. However, arterial
blood sampling in mice is difficult, and other methods have
been accepted for kinetic analysis [14,15]. For 123I-labeled
tracers, good correlation has been demonstrated using the
semiquantitative index of the specific DAT binding, re-
ferred to as binding potential (BP). BP is a ratio of the spe-
cific to nonspecific binding of DATs (such as the striatum
and cerebellum). BP is directly proportional to the density
of DATs in the equilibrium state [14,15]. We used BP to
analyze the 123I-β-CIT ratios in the kinetics and test-retest
studies of mice.
The 123I-β-CIT and FP-CIT are both clinically available
and specific for use in PD diagnostics [16]. Here, we
used 123I-β-CIT for several reasons: First, more rapid
wash-up of the FP-CIT may cause underestimation of
DAT density in patients [17]. Second, more rapid kinet-
ics of FP-CIT in patients is even further accelerated in
mice, which makes 123I-β-CIT more suitable for investi-
gating disease models or pharmaceutical effects in mice.
Third, with 123I-β-CIT, higher binding ratios have been
reported in humans [17], which improve the signal-to-
noise ratio in images acquired from the mouse brain.
To demonstrate the feasibility of the DAT tracer 123I-β-CIT
in preclinical research in mice, we established the kinetics
of the tracer with high-resolution SPECT/CT imaging.
Furthermore, we validated the steady-state conditions of
the tracer in the brain and evaluated the reproducibility of
the method in test-retest measurements. Our second ob-
jective was to create a normal template to be used as a fu-
ture reference frame for the coregistration and analysis of
the mice with altered DAT production.
Methods
SPECT/CT system
SPECT/CT imaging was performed using a preclinical
four-headed gamma camera with integrated CT system
and dedicated multipinhole collimators, comprising in
all 36 1.0-mm pinholes (nanoSPECT/CT, Bioscan Inc.,Washington, DC, USA). The manufacturer states that
the sensitivities of the pinhole collimators are >1,200
counts per second (cps)/MBq, with a maximum reso-
lution of ≤0.75 mm. The scanning mode is helical for
both modalities.
Phantom studies
The spatial resolution of the system was verified for 123I,
using a Jaszczak phantom with hot rods ranging from
0.7 to 1.2 mm (Bioscan Inc., Washington, D.C., USA).
The phantom was filled with 75 MBq of 123I-NaI (MAP
Medical Technologies Oy, Tikkakoski, Finland), and the
images were acquired in 32 projections, using 150 s per
gantry position. The imaged data were reconstructed
with HiSPECT NG software (Scivis GmbH, Göttingen,
Germany).
Animals
The animal experiments were reviewed and approved by the
Finnish National Animal Experiment Board and performed
in accordance with Good Laboratory Practices for Animal
Research. Triple-mixed genetic background 129Ola/C57BL/
6/ICR mice were backcrossed once to the 129Ola line, and
4-month-old male progenies were used in the SPECT
experiments. The animals were maintained under isoflurane
inhalation anesthesia during radiotracer administration and
imaging. Under anesthesia, body temperature of the animals
was maintained using a heated animal bed (37°C) (Minerve,
France), during imaging, and with a heating pad under the
cage, between imaging sessions.
SPECT/CT imaging
All mice (n = 8) received 34 to 41 MBq of 123I-β-CIT
(MAP Medical Technologies Oy) in <200 μl intraven-
ously. Kinetics study mice (n = 3) received 34 to 41
MBq of 123I-β-CIT. The test-retest mice received 1.12 ±
0.08 MBq/g body weight (b.wt.) and 0.94 ± 0.07
MBq/g b.wt., respectively.
At the early time points (from 20 min to 2 h 30 min)
of the kinetics experiments (n = 3), the data were
acquired dynamically with a scanning length of 15 min
(angular step 15°, 24 projections, 150 s per gantry pos-
ition). At the late time points (at 4 h and 7 h), the scan-
ning length was 25 min (angular step 15°, 24 projections,
250 s per gantry position). In all, 11 time points were
collected from the mice. The data were acquired in a
128 × 128 matrix with pixel size and a slice thickness of
0.2 mm.
CT was acquired at 20 min and later at 4 and 7 h. The
CT parameters used in the present work were as follows:
180 projections, pixel size of 192 × 192 μm, X-ray source
of 45 kVp, and exposure time of 500 ms. Helical scan-
ning is used by both modalities and is performed by
moving the animal through the SPECT and CT.
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imaged 4 h postinjection, which was confirmed to be the
equilibrium time point in the kinetics study. The same
animals went through the same protocol after 8 days.
The same SPECT protocol was used as described for the
late time points in the kinetics experiment.
Data analysis: kinetics experiment
The data were reconstructed in the system's dedicated
reconstruction program with an iterative reconstruction
algorithm, resulting in a voxel size of 0.3 mm. After
image reconstruction, the images were straightened and
analyzed using InVivoScope software (Bioscan Inc.).
Straightening of the images was assisted by the CT
images. To avoid the variability of the slice selection and
to gain statistical power, we used the entire striatum vol-
ume for the analysis. Time-activity curves were obtained
from the kinetics data by manually delineating the
volumes of interest (VOIs). At each time point, the VOIs
were drawn over specific (striatal) and nonspecific (cere-
bellar) brain structures, and the mean counts in these
two areas were measured against time. From the mean
values obtained, we calculated the BP, which represents
the ratio of the distribution volumes of the specifically
and the nonspecifically bound compartment.
Data analysis: test-retest experiment
Following data reconstruction, the images were first
manually straightened and converted from Dicom to the
Analyze format [18] and further processed in Vinci
(S. Vollmar et al., Cologne, Germany) [19]. In Vinci, the
images were first masked to remove the eyes and other
possible high-uptake areas external to the brain. Then, all
the images were normalized individually using the average
value of the voxels within 95% of the maximum count
value in the striatal volume. Finally, both time points wereFigure 1 Jaszczak phantom. The spatial resolution of the system was ver
to 1.2 mm. Images were acquired in 32 projections, using 150 s per gantry
demonstrates the spatial resolution of the system. The red line in the SPEC
(b) is captured. The 0.8-mm hot rods are clearly detectable.registered to the SPECT template (see below), which
served as a reference space and defined the VOIs. The
mean count density per pixel in each region was calcu-
lated and corrected for the effects of decay. The test-retest
variability was calculated as the absolute difference of two
measurements divided by the mean of two measurements
as a percentage. Comparison between the test and retest
time points was achieved by the Wilcoxon signed rank
test.
Creation of template
Two separate templates were aggregated from the test and
retest mice groups. The images were first manually straigh-
tened, masked, and normalized to 95% of the maximum
count value. Secondly, the images were spatially coregis-
tered using an affine transformation algorithm with mutual
information as a similarity measure for registrations. Then,
the average and standard deviation templates were calcu-
lated using the spatial- and count-normalized images. Fi-
nally, the anatomical areas were confirmed by coregistering
the SPECT template to an available magnetic resonance
imaging (MRI) brain template [20]. Comparison between
the test and retest templates was achieved by voxel-by-
voxel t test.Results
SPECT imaging of phantom
Prior to the animal studies, we evaluated the perform-
ance of the scanner for spatial resolution. Under the
conditions of high radioactivity (75 MBq), acquisition
time (20 min), and reconstruction parameters for fine
image quality, the resolution was superior. Figure 1
shows the SPECT images and their count profile curves
of the Jaszczak phantom filled with 123I-Na, yielding an
excellent spatial resolution with good visualization of
hot rods as thin as 0.8 mm.ified for 123I, using a Jaszczak phantom with hot rods ranging from 0.7
position. Jaszczak phantom, filled with 75 MBq of 123I-Na,
T image (a) represents the area where the count profile curve
Figure 2 Coregistered template. In building the template, the anatomical areas are confirmed by coregistering the template to an available
MRI brain template [20]. Coregistration is visualized so that SPECT is in color and MRI is in gray scale.
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Templates were compared using voxel-by-voxel t test,
and no significant differences were found between test
and retest. Figure 2 shows the outcome of coregistration
between the created SPECT template and MRI template.
The anatomical areas seem to be equivalent between
SPECT and MRI (Figure 2).
In the individual animals and the template, the anatom-
ical volume of the striatum was estimated by several
thresholds from the maximum intensity of the structure
(Figure 3). From the template, we obtained a striatal
volume of approximately 22.3 mm3 by choosing a thresh-
old of 50% of the maximum intensity of the striatumFigure 3 Striatal volumes. Mice (n = 5) received 1.12 ± 0.08 MBq/g
b.wt. of 123I-β-CIT. They were imaged 4 h postinjection, and
scanning length was 25 min (angular step 15°, 24 projections, 250 s
per gantry position). The data were acquired in a 128 × 128 matrix
with pixel size and a slice thickness of 0.2 mm. The anatomical
volume of the striatum was estimated by several thresholds from
the maximum intensity of the structure. A striatal volume was
measured for the template and individual mice by choosing a
threshold of 50% of the maximum intensity of the striatum (vertical
line), which resulted as a striatal volume of 22.3 mm3 and 17.2 mm3
± 20%, respectively.(Figure 3). When performing the same analysis for individual
animals, we obtained a striatal volume of 17.2 mm3 ± 20%
(Figure 3).
Dopaminergic terminals are present at high density in
the striatum but are less dense in the cerebellum, which
makes delineation of the nonspecific uptake area very diffi-
cult. Thus, the cerebellar VOI was chosen to consist of
only part of the cerebellum (13.3 mm3) to avoid delineation
of those areas that consist of counts due to scattered or
partial volume effects. Meanwhile, the cerebellar volume
should be sufficiently large to gain enough statistics for
calculation of a reliable BP.
Kinetics study of mice
In the kinetics experiment, a total of 11 time points were
imaged, starting at 20 min and ending at 7 h postinjec-
tion (Figure 4a). In the striatum, the amount of activity
increased gradually and peaked at approximately 2 to 3
h (Figure 4b). After 4 h, the striatum uptake washed out
gradually. The nonspecific binding area, the cerebellum,
showed no binding and half of the activity dissipated
in 2.5 h. The ratio of the specific binding value of
123I-β-CIT to nonspecific uptake, BP, became constant 2 h
postinjection (Figure 4c). After 4 h, BP shows a gradual in-
crease. Symmetrical striatal binding was visible in the
SPECT images at 4 h postinjection (Figure 4a). Harder's
glands showed radioactivity uptake (Figure 4a).Test-retest study
In the test-retest study, the 4-h time point was set as the
acquisition time, based on the kinetics experiment. The
same animals followed the same protocol after 8 days.
The individual BP values obtained from each mouse are
shown in Figure 5. The mean BP values of the test-retest
studies were 6.6 ± 15.7% and 6.6 ± 4.6% (mean ± relative
standard error), respectively, and these measures did not
differ statistically from each other (P = 0.968). The test-
retest variability was 9%.
Figure 4 Kinetics experiment data. Mice (n = 8) received 34 to 41 MBq of 123I-β-CIT. At the early time points (from 20 min to 2 h 30 min) post-
tracer injection, the data were acquired dynamically with a scanning length of 15 min (angular step 15°, 24 projections, 150 s per gantry position).
At the late time points (at 4 h and 7 h), the scanning length was 25 min (angular step 15°, 24 projections, 250 s per gantry position). The data
were acquired in a 128 × 128 matrix with pixel size and a slice thickness of 0.2 mm. In all, 11 time points were imaged (a). Time-activity curves
were obtained from the kinetic data by manually delineating the VOI (b). At each time point, the VOIs were drawn over specific (striatal) and
nonspecific (cerebellar) brain structures, and the mean counts in these two areas were measured against time. Specific-to-nonspecific BP was
calculated (c).
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Figure 5 Binding potential values. The test and retest mice (n = 5) received 1.12 ± 0.08 MBq/g b.wt. and 0.94 ± 0.07 MBq/g b.wt. of 123I-β-CIT,
respectively. Mice were imaged with the equivalent protocol in the test and retest time points; scanning length was 25 min (angular step 15°, 24
projections, 250 s per gantry position). The data were acquired in a 128 × 128 matrix with pixel size and a slice thickness of 0.2 mm. Individual BP
values were obtained at 4 h postinjection on each of the five mice at both test and retest (8 days later), with the corresponding mean and
standard deviation. The test-retest measurements were insignificantly different (P = 0.968).
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The primary aim of this study was to demonstrate that
small-animal SPECT/CT imaging is capable of measur-
ing DAT density. We validated a DAT-binding imaging
protocol for the mouse brain, using 123I-β-CIT. To our
knowledge, the present study is the first to demonstrate
the 3D kinetics of 123I-β-CIT in mice, using SPECT/CT
imaging.
The SPECT/CT used was equipped with four collima-
tors and apertures, each with nine 1-mm pinholes, result-
ing in high counting rates. The resolution for the camera
was in the submillimeter range; Jaszczak phantom imaging
showed that we can reliably image the mouse striatum.
From the template, we obtained a striatal volume of
approximately 22.3 mm3 with a threshold of 50% of the
maximum intensity of the striatum. Similar striatal
volumes have been reported in equivalent strains [21]. At
the same threshold, we obtained a striatal volume of 17.2
mm3 ± 20%. In Figure 3, the striatal volume is shown as a
function of thresholds in individuals and the template.
The striatal volume increases until it becomes stable at ap-
proximately 50% to 60% of the maximum activity. The
phenomenon was found in both cases (Figure 3). For
threshold values higher than 60%, the volume spreads out-
side the striatal volumes, into other parts of the brain. The
higher striatal volume in the template is due to individual
variation, coregistration, and averaging. This comparison
indicates that the template represents data in healthy mice
well and that no coregistration or technical problems oc-
curred. Further, we compared the templates created fromthe first and second imaging of the test-retest study and
found no significant difference. This result demonstrates
that our method has good repeatability. In future works,
we will address individual variation in striatal structures
and minimize the processing steps needed using the
template.
In the present study, we report the kinetics of the
123I-β-CIT tracer in the striatum and cerebellum. As indi-
cated earlier, the quantitative validity of the BP method
(striatal to background brain region ratio) depends on the
achievement of steady levels of activity in these regions
[17]. As shown in Figure 4b, 3 h postinjection, there is par-
allel washout in cerebellum and striatal volumes. Thus, BP
analysis can be considered valid 4 h post-123I-β-CIT injec-
tion in the mouse brain. These results agree with the earlier
autoradiography works [7-9]. However, our results show
moderate increase in BP, which is evident at the 7-h im-
aging point. This might be due to the individual kinetics of
mice and also because of low statistics in the cerebellum
volume. To resolve this, further kinetic studies should be
performed at late imaging points.
We used BP to perform semiquantitative analysis of
dopaminergic neurotransmission post-123I-β-CIT injec-
tion. BP increased over the time period followed, similar
to previous rat studies with SPECT [11,12] and autoradi-
ography work with both rats [22] and mice [7-9]. In
healthy human subjects, the evolvement of BP is similar,
differing only by time scale [23,24], due to the slower me-
tabolism of humans compared with mice. In the present
work, 4 h postinjection was a suitable time point for use
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in human patients [23,24].
In the test-retest study, one of the five animals showed a
clearly larger variation among BPs, which probably resulted
from unsuccessful injection at either one of the time
points. The variability between test and retest was clearly
better than that in healthy human subjects [25,26], which
shows that our method has good test-retest reproducibility.
Such improvement was expected, due to the better sensi-
tivity and resolution of the small-animal SPECT instru-
ment compared with clinical systems.
Successful validation of the imaging protocol and estab-
lishment of the template will help to reduce the number
of control mice needed for the experiments and will fur-
ther reduce the overall costs and time needed. The tem-
plate created here will be further used as a reference to
differentiate between normal and genetically modified
mouse DAT densities. Also, we are planning to extend the
template to include serotonin transporters. In present and
future works, the template will offer a reference for core-
gistration and will take into account the variance between
individuals in the VOI analysis. Furthermore, correct and
repeatable delineation of VOIs is needed to gain enough
statistical power because the targets are submillimeter in
size. Herein, we focused on certain VOIs, but the template
may also be used in voxel-by-voxel analysis.
Conclusions
We have demonstrated explicitly that high-resolution,
multipinhole SPECT/CT of mice is capable of accurate,
repeatable, and semiquantitative measurement of DAT
binding, using 123I-β-CIT. This methodology should in-
crease the opportunities for further study of cerebral
binding sites, especially in mice.
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